(Wired) – Rosas’ case illustrates the reality of new anti-obesity drugs: They don’t work equally well for everyone. Semaglutide, which goes by the brand names Ozempic and Wegovy, has shown around 15 percent weight loss in clinical trials, while tirzepatide—sold as Mounjaro and Zepbound—has achieved around 20 percent. But those are averages, and in the real world, drugs don’t always perform as well as they do in carefully controlled trials. (Read More)